source
- FDA and Capricor clash over Duchenne cell therapy efficacy at advisory committeeAt an FDA advisory committee meeting, the agency and Capricor Therapeutics presented conflicting views on the efficacy data for the company's experimental cell therapy aimed at Duchenne muscular dy…
- Vertex and AbCellera team up to develop next-generation T-cell engagers for autoimmune diseasesVertex Pharmaceuticals has entered a partnership with AbCellera to create next-generation T-cell engagers aimed at autoimmune diseases. AbCellera will receive an upfront payment of $28 million, wit…